Photo of Slates C. Veazey

Slates is a member of Bradley’s Cannabis Industry team, advising clients on a variety of cannabis issues and in a wide range of sectors. From individuals and entities interested in participating in the new Mississippi medical cannabis program to non-plant-touching companies impacted by that emerging market, Slates and his partners provide the full suite of services that Bradley offers to its many other clients -- but with a specific understanding of the ever-changing cannabis industry. His work has been featured in The National Law Journal, JD Supra, and the Cannabis Business Executive. Slates also has been quoted by the Mississippi Business Journal and Mississippi Today regarding Mississippi’s medical cannabis program.

Now that the dust is starting to settle on the recent news that the U.S. Department of Health and Human Services (HHS) has recommended to the U.S. Drug Enforcement Agency (DEA) that marijuana be moved from Schedule I to Schedule III under federal law, it is important to understand the implications of rescheduling marijuana and

Those long-awaited proposed revisions to the Mississippi Department of Health’s medical cannabis program regulations dropped last Thursday afternoon. Thankfully, the department released a red-lined version, highlighting exactly what they are proposing to change and add to the existing regulatory framework. And goodness is there a lot of red! The department is accepting comments from

According to a report from Bloomberg News, the U.S. Department of Health and Human Services (HHS) is officially recommending to the U.S. Drug Enforcement Agency (DEA) that marijuana be moved from Schedule I to Schedule III under federal law. The move follows a directive issued by President Biden last year that Secretary of Health

A question frequently encountered in the cannabis industry involves a cannabis user’s gun rights. This stems from the ever-present federal and state law tension overlaying marijuana in the United States — thanks to the Schedule 1 status of “marihuana” under the Controlled Substances Act. A Westlaw search quickly reveals that over the past year federal

Pursuant to the Mississippi Medical Cannabis Act, Mississippi residents can petition the state’s Department of Health to add new serious medical conditions or their treatments to the existing list of conditions that qualify a prospective patient for a medical marijuana card (Miss. Code Ann. § 41-137-17). Exercising this authority, the DOH recently made it easier

Word began circulating a few days ago that tobacco giant Philip Morris has agreed to purchase Israeli cannabis company Syqe Medical for a whopping $650 million if certain future events come to fruition.  While the two companies evidently have some history together, this new deal is reportedly tied to Philip Morris’ interest in acquiring Syqe’s

Marshall Jones is a co-author of this post, and is a Summer Associate at Bradley.

I sound like a broken record, but I will say it again: To remain compliant in the cannabis industry requires an almost constant state of diligence. This point was reinforced earlier this month when the Mississippi Department of Health

420. A celebrated day where buds get together and consume copious amounts of cannabis… blog posts. This Cannabis Day, we are celebrating the 1-year anniversary of launching the Budding Trends blog and are sharing our first annual “Weed Roundup.” Featuring our top 10 most read blog posts of the year, the inaugural Weed Roundup is

If you haven’t heard, the patient numbers in Mississippi’s new medical cannabis program are not rising at the pace many hoped they would. This has caused quite a bit of concern across the industry down here. A healthy pool of patients is critical to keeping new cannabis businesses afloat due to the hefty initial expenses

Welcome to the latest installment of the Editors’ Roundtable, in which our editors – Whitt SteinekerJay WrightHunter Robinson, and Slates Veazey – discuss cannabis issues in the news and take a stab at where the cannabis industry is going in the future.

Whitt Steineker (WS): Oh, boy. We have a